

1 **Carotid body dysregulation contributes to the enigma of long COVID**

2 Ahmed El-Medany*^{1,2,3}, Zoe H Adams*¹, Hazel C Blythe*¹, Katrina A Hope^{1,4}, Adrian
3 H Kendrick^{1,5}, Ana Paula Abdala Sheikh¹, Julian FR Paton⁶, Angus K Nightingale^{1,3},
4 Emma C Hart¹

5 *Contributed equally to first authorship.

6 ¹ School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol,
7 UK.

8 ² Department of Cardiology, Southmead Hospital, North Bristol NHS Trust, Bristol,
9 UK.

10 ³ Bristol Heart Institute, University Hospitals Bristol and Weston NHS Foundation
11 Trust, Bristol, UK.

12 ⁴ Department of Anaesthetics, Southmead Hospital, North Bristol NHS Trust, Bristol,
13 UK.

14 ⁵ Department of Respiratory Medicine, University Hospitals Bristol and Weston NHS
15 Foundation Trust, Bristol, UK.

16 ⁶ Manaaki Manawa, The Centre for Heart Research, University of Auckland,
17 Auckland, New Zealand.

18

19 **Abstract**

20 The symptoms of long COVID, which include fatigue, breathlessness, dysregulated
21 breathing, and exercise intolerance, have unknown mechanisms. These symptoms
22 are also observed in heart failure and are partially driven by increased sensitivity of
23 the carotid chemoreflex. As the carotid body has an abundance of ACE2 (the cell
24 entry mechanism for SARS-CoV-2), we investigated whether carotid chemoreflex
25 sensitivity was elevated in participants with long COVID. During cardiopulmonary
26 exercise testing, the V_E/V_{CO_2} slope (a measure of breathing efficiency) was higher
27 in the long COVID group than in the controls, indicating excessive hyperventilation.
28 The hypoxic ventilatory response, which measures carotid chemoreflex sensitivity,
29 was increased in long COVID participants and correlated with the V_E/V_{CO_2} slope,
30 suggesting that excessive hyperventilation may be related to carotid body
31 hypersensitivity. Therefore, the carotid chemoreflex is sensitized in long COVID and
32 may explain dysregulated breathing and exercise intolerance in these participants.
33 Tempering carotid body excitability may be a viable treatment option for long COVID
34 patients.

35 Introduction

36 Long COVID (post-COVID-19 syndrome), is a multi-organ, often debilitating
37 condition associated with a range of symptoms. The UK's National Institute for
38 Health Care and Excellence (NICE) defines long COVID as ongoing symptoms
39 lasting for 12 or more weeks after initial SARS-CoV-2 infection, without alternative
40 explanations¹. The estimated incidence of long COVID varies, and is reported to be
41 up to 41% of non-hospitalised cases^{2 3 4} and up to 76% of hospitalised cases^{5 6}. The
42 prevalence decreases in vaccinated populations⁷. In January 2023, 2 million people
43 self-reported long COVID symptoms in the UK, with 77% experiencing adverse
44 effects in their daily activities⁸. Persistent symptoms include chronic fatigue, 'brain
45 fog,' cognitive impairment and memory loss, dyspnoea at rest and on exertion,
46 exercise intolerance, orthostatic intolerance, inappropriate postural tachycardia, and
47 episodic hyperadrenergic surges^{4,9,10}. A meta-analysis of 63 studies worldwide, with
48 a total COVID-19 population of 257,348, reported that between 3-6 and 9-12 months
49 post-infection, fatigue and dyspnoea were the most reported symptoms, with a
50 prevalence of 32-47% and 21-25% respectively¹¹. Despite the prevalence of long
51 COVID and severely disabling symptoms there are no treatment strategies available.
52 Thus, it is crucial to identify the mechanisms involved in long COVID to inform
53 urgently needed therapy. It is likely that mechanisms depend on the severity of the
54 original infection and are different for hospitalised (e.g. long term sequelae from
55 intensive care and intubation/ventilation) versus non-hospitalised patients who had
56 mild to moderate initial symptoms.

57 Currently, the exact mechanisms driving long COVID in non-hospitalised patients
58 remain unknown but are likely to be multiple^{12,13}. Studies have shown that exercise
59 intolerance and disorganised breathing or breathing inefficiency during exercise are
60 key features of long COVID¹⁴⁻¹⁷ even in patients who have normal lung function and
61 no evidence of gas exchange abnormalities¹⁶. The carotid bodies are key oxygen,
62 carbon dioxide and pH sensing organs that control ventilation, dyspnoea, and the
63 circulation at rest and during exercise in health and disease^{18,19}. In fact, in chronic
64 heart failure the carotid chemoreflex becomes chronically sensitised as a
65 compensatory mechanism, and is associated with a worse prognosis²⁰, exertional
66 dyspnoea, dysfunctional or inefficient breathing, and poor exercise tolerance²¹,
67 similar to symptoms in patients with long COVID who do not have heart failure.

68 SARS-CoV-2 infects host cells via binding of its receptor-binding domain to the
69 membrane bound angiotensin-converting enzyme 2 (ACE2)²². ACE2 is abundant in
70 the carotid bodies²³. A role of the carotid chemoreflex in the acute phase of the
71 infection is supported by reports of silent hypoxia^{23,24}, SARS-CoV-2 invasion of
72 glomus cells (main oxygen sensing cells) and microembolism within the small
73 arteries supplying blood to the carotid body^{25,26}. The carotid bodies express their own
74 renin-angiotensin system^{27,28}, where normal functioning is dependent on the balance
75 of ACE1 and ACE2²⁷. Disruption of this local system causes increased carotid
76 chemoreflex activity^{28,29}. Thus, disturbances in the carotid body following SARS-
77 CoV-2 infection; by viral invasion, blood flow disruption and local immune responses
78 could cause chemoreceptive dysfunction, by increasing local ACE1/ACE2 imbalance
79 (in favour of higher ACE1 expression versus ACE2) and angiotensin II receptor
80 stimulation^{25,30}.

81 We propose that carotid body dysfunction occurs in long COVID, which contributes
82 to dysregulation of ventilation and cardiovascular control, especially during exercise.
83 Therefore, we conducted a case-control study to determine whether carotid
84 chemoreflex sensitivity is elevated in non-hospitalised patients with long COVID and
85 whether this could help to explain impairments in exercise tolerance and
86 dysregulated breathing reported during exercise in non-hospitalised patients with
87 ongoing symptoms. We hypothesised that long COVID patients would exhibit
88 increased hypoxic ventilatory responses at rest and poorer ventilatory efficiency
89 during exercise compared to controls.

90

91 **Results**

92 *Participants*

93 Supplementary Figure 1 shows recruitment, screening, cases excluded and the final
94 sample size. Sixty-four individuals contacted the group about the study, and all were
95 sent a participant information sheet. Of these, 32 replied and completed phone
96 screening. Six were excluded due to screen failure (met exclusion criteria). Twenty-
97 six participants were recruited (long COVID n=16 and controls n=10). Two
98 participants (1 long COVID and 1 control) did not complete the study since they
99 could not tolerate the mask for spirometry, 1 long COVID participant was excluded

100 during the study visit due to identification of cardiac disease (valve disease or non-
101 benign arrhythmia) and 1 participant was excluded between visits due to diagnosis of
102 gout (control). The final sample size was 14 participants with long COVID and 8
103 controls (recovered from initial viral infection within 4 weeks without ongoing
104 symptoms). Data sets from six healthy participants from a previous study (NHS REC
105 numbers: 17/SW/0171 and 18/SW/0241), completed before the SARS-CoV-2
106 pandemic using the same methods, equipment, and location (clinical room) were
107 added to the control group. These participants were identified based on age, sex,
108 and body mass index (BMI) so that they matched the participants in the long COVID
109 study.

110 Participant demographics are shown in Table 1. Age, BMI, height, and body mass
111 were similar between the control and long COVID groups ($P>0.05$). Clinic systolic
112 blood pressure (SBP), diastolic BP (DBP) and heart rate (HR), were not different
113 between groups ($P>0.05$).

114 All participants who had COVID-19 were first infected from April 2020 to December
115 2021, when the dominant variants of SARS-CoV-2 were the original virus, Alpha,
116 Delta, and Omicron. The average number of days since first infection to the study
117 visit, in the long COVID and control groups, were similar (Table 1, $P=0.1006$). As per
118 the exclusion criteria, none of the participants were hospitalised (admitted) for
119 COVID-19 and had a previous positive PCR test at the time of the initial infection or
120 were seropositive for SARS-CoV-2 antibodies (see inclusion/exclusion criteria in
121 methods). The initial infection caused mild to moderate symptoms in all participants.
122 Table 2 outlines the most common ongoing symptoms previously reported^{9,31,32} and
123 the percentage of the long COVID participants in this study reporting these
124 symptoms. Long COVID participants reported at least 3 symptoms, with the most
125 common symptoms being dyspnoea at rest and on exertion, extreme fatigue, “brain
126 fog” and chest pain.

127 Ten out of the 14 long COVID participants had been seen in a cardiology outpatient
128 long COVID clinic at a UK based University Hospital NHS Trust, where structural
129 cardiac disease (e.g., myocarditis, heart failure, ischaemia) had been excluded. All
130 the participants reporting chest pain were reviewed in a cardiology clinic, which was
131 diagnosed as non-cardiac in origin. None of the long COVID participants (or controls)

132 had been diagnosed with pre-existing cardiovascular or pulmonary diseases. Four of
 133 the long COVID participants had been prescribed ivabradine in the cardiology
 134 outpatient long COVID clinic. These participants stopped taking ivabradine 48 hours
 135 before their study visits (plasma half-life: 2 hours and effective half-life: 11 hours).
 136 Severe asthma was an exclusion criterion, however 2 controls and 6 long COVID
 137 participants had been previously diagnosed with mild asthma (before COVID). All
 138 participants had a normal resting 12-lead ECG, which was completed as part of the
 139 study screening process. Twelve of the 14 long COVID participants self-reported
 140 having a chest x-ray, all of which were normal. Finally, Supplementary Table 1
 141 provides information of drugs prescribed in both groups.

142 Table 1 - Demographic, spirometry, and SARS-CoV-2 infection data.

Demographics	Controls (n=14)	Long COVID (n=14)	P-value
Sex (M/F)	3/11	2/12	-
Age (years)	35 ± 13	42 ± 12	0.1195
BMI (kg/m²)	24.5 ± 4.9	26.9 ± 5.3	0.2140
Height (cm)	166 ± 5	167 ± 7	0.5543
Body mass (kg)	67.2 ± 12.9	75.1 ± 16.3	0.1573
Received all recommended COVID-19 vaccinations at time of study (%)	100%	100%	-
Time since initial infection (days) [median (IQR)]	473 (265-543)	534 (400-709)	0.1006*
Clinic BP			
SBP (mmHg)	121 ± 9	131 ± 17	0.0732
DBP (mmHg)	75 ± 7	83 ± 13	0.0594
HR (beats/min)	69 ± 12	75 ± 12	0.1895
Resting lung function			
n	11	14	
FEV₁ (z-scores)	-0.32 ± 0.92	-0.90 ± 1.23	0.2109
FVC (z-scores)	-0.56 ± 1.01	-1.03 ± 0.86	0.2279
FEV₁/FVC (z-scores)	0.60 ± 0.95	0.21 ± 1.13	0.3727
FEF_{75%} (z-scores)	0.61 ± 1.01	0.43 ± 0.77	0.6191

143 *Mann Whitney U. BMI; body mass index, IQR; interquartile range, BP; blood
144 pressure, SBP; systolic blood pressure, DBP; diastolic blood pressure, HR; heart
145 rate, FEV₁; forced expiratory volume in 1 second, FVC; forced vital capacity, FEF_{75%};
146 forced expiratory flow after 75% of the FVC has been exhaled. Note that the control
147 group includes data from 6 participants data who took part in studies in the same
148 laboratory before the pandemic and did not have COVID-19. Thus, the data
149 pertaining to vaccines and infections is for the 8 participants recruited who had
150 COVID-19 infection but did not develop ongoing symptoms.

151 Table 2 - Common ongoing symptoms reported in post COVID-19 syndrome and
152 the % of participants in the present study, self-reporting these symptoms.

Symptoms	Long COVID (n=14)
At least 3 symptoms	100%
Dyspnoea on exertion	92%
Dyspnoea at rest	86%
Brain fog	86%
Fatigue	79%
Chest pain	50%
Palpitations or tachycardia	36%
Dizziness	36%
Post-exertional malaise	36%
Muscle or joint pain	21%
Oedema in extremities	14%
Nausea	14%
Chronic dry cough	14%
Impaired taste or smell	7%
Alopecia	7%
Chronic fever	0%
Diarrhoea	0%

153

154 *Resting spirometry*

155 Spirometry data are summarized in Table 1 and are presented as z-scores with a
156 normal z-score being between ± 1.64 ³³. There were no differences between the two
157 groups for FEV₁ (forced expiratory volume in 1 second), FVC (forced vital capacity),

158 FEV₁/FVC and FEF_{75%} (forced expiratory flow after 75% of the FVC has been
159 exhaled; P>0.05). No participants had an FEF_{75%} smaller than -1.64 z-score,
160 therefore excluding small airway disease. One control subject and 3 long COVID
161 participants had a reduced FEV₁ and FVC with a normal FEV₁/FVC ratio, suggestive
162 of a restrictive ventilatory defect. One long COVID participant had a reduced FEV₁
163 and FVC, with an FEV₁/FVC ratio consistent with an obstructive ventilatory defect
164 (z-score = -3.25) indicating severe airflow obstruction (z-score = - 3.85)³³.

165 *Sit to standing blood pressure test*

166 To check for orthostatic intolerance in both groups, a sit-to-standing test (like that
167 used in the HYVET study^{34,35}) was completed (3 mins of standing). Sit-to-stand was
168 completed in all long COVID participants and 8 of the controls. BP was measured at
169 seated rest, immediately after standing, 1 min, 2 mins and 3 mins of standing.
170 According to HYVET study guidelines, a fall in SBP>15 and DBP>7 mmHg was used
171 as a diagnosis of orthostatic intolerance. During standing, the mean SBP and DBP
172 did not fall by more than 15 and 7 mmHg in either group at any time point ³⁴
173 (Supplementary Figure 2; Supplementary Table 2 for mean change data). Two
174 control participants had a fall in SBP >15 or DBP >7 mmHg, and 1 participant from
175 the long COVID group met this criterion (supplementary figure 2). Mean data at each
176 timepoint were analysed using a mixed model ANOVA. Interestingly, we found that
177 the increase in HR was larger in the control group versus the long COVID group
178 (main Time*Group effect; P=0.0258, see supplementary results for ANOVA details
179 and figure 2).

180 *Resting cardiopulmonary data*

181 The resting HR, BP, minute ventilation, tidal volume and breathing frequency were
182 similar between groups (Table 3, P>0.05). Resting partial pressure of the end tidal
183 CO₂ (P_{ET}CO₂) was lower in the long COVID group (range: 22 to 34 mmHg versus
184 controls (range: 30-36 mmHg, Table 3, P=0.0378). The minute ventilation was
185 similar between groups despite a lower P_{ET}CO₂ in the long COVID group. This was
186 coupled with a higher ventilation for the volume of CO₂ expired (V_E/VCO₂ ratio,
187 P=0.0246); suggesting that there is some hyperventilation occurring at rest in the
188 long COVID group. There were no differences in the expiratory and inspiratory times,
189 or the ratio of inspiration to expiratory times between groups (P>0.05; Table 3 for

190 exact P-values). Interestingly, the tidal volume/inspiratory time ratio (V_T/T_i ; an index
 191 of inspiratory flow³⁶) was 16% higher in the long COVID group versus the controls
 192 ($P=0.0483$) indicative of increased inspiratory drive.

193 Table 3 - Resting cardiopulmonary variables in controls versus long COVID.

Resting cardiopulmonary data	Controls (n=14)	Long COVID (n=14)	P-value
SBP (mmHg)	112 ± 9	118 ± 16	0.1603
DBP (mmHg)	75 ± 8	80 ± 16	0.1985
HR (beats/min)	76 ± 9	83 ± 11	0.0886
V_E (L/min)	9.2 ± 2.1	10.1 ± 2.8	0.3434
V_T (mL)	609 ± 115	659 ± 173	0.3546
f_B (breaths/min)	15 ± 3	16 ± 3	0.8938
T_i (secs)	1.65 ± 0.37	1.60 ± 0.41	0.7934
T_e (secs)	2.86 ± 0.61	2.77 ± 0.81	0.7509
T_i/T_e	0.59 ± 0.08	0.59 ± 0.12	0.9062
V_T/T_i	0.37 ± 0.07	0.43 ± 0.09	0.0483
$P_{ET}CO_2$ (mmHg)	33.5 ± 2.6	30.9 ± 3.7	0.0378
VO_2 (L/min)	0.25 ± 0.05	0.24 ± 0.05	0.5781
VCO_2 (L/min)	0.22 ± 0.04	0.21 ± 0.05	0.8006
V_E/VCO_2 ratio	42.2 ± 4.4	48.0 ± 8.3	0.0246

194 SBP; systolic blood pressure, DBP; diastolic blood pressure, HR; heart rate, V_E ;
 195 minute ventilation, V_T ; tidal volume, f_B ; breathing frequency, T_i ; inspiratory time, T_e ;
 196 expiratory time, V_T/T_i ; inspiratory flow index, $P_{ET}CO_2$; end-tidal partial pressure of
 197 carbon dioxide, VO_2 ; volume of inspired oxygen, VCO_2 ; volume of expired carbon
 198 dioxide.

199

200

201

202 *Cardiopulmonary exercise testing*

203 Cardiopulmonary exercise testing (CPET) was completed on a cycle ergometer to
 204 peak oxygen consumption (VO_2 peak) to assess exercise tolerance and identify any
 205 breathing or cardiovascular abnormalities that might not be evident at rest. We also

206 wanted to understand whether any dysfunctional breathing (defined here as
207 inappropriate hyperventilation or poor breathing efficiency characterised by elevated
208 minute ventilation/volume of CO₂ expired (V_E/V_{CO_2}) slopes¹⁷) during exercise could
209 be linked to carotid chemoreflex hyperactivity in the long COVID group versus
210 control.

211 To assess whether maximal effort was achieved and as an objective assessment of
212 the quality of the test, a respiratory exchange ratio >1.15, maximum predicted
213 HR >85%, rating of perceived exertion (RPE; 6-20 Borg Scale) of 17-20 and a
214 plateau in VO₂ were used. Overall, 86% of the control group and 86% of the long
215 COVID group achieved these criteria. Thus, differences between groups are likely
216 not due to differences in effort or quality of the CPET. In fact, the control group
217 reported a lower RPE at peak exercise (17; 17-18 (median, IQR)) versus the long
218 COVID group (19; 18-19, P=0.0081; Mann Whitney U). Table 4 shows the mean ±
219 SD (range) for all CPET variables. None of the participants desaturated during the
220 test (defined as SpO₂% < 95%, where peak SpO₂% was similar between groups), and
221 there were no exercise induced cardiac ischaemic changes observed on the 12-lead
222 ECG.

223 The VO₂ peak measured in L/min, mL/kg/min and as a % of peak predicted were
224 lower in the long COVID group versus controls (Table 4; P<0.05). Absolute VO₂ at
225 anaerobic threshold (AT) was also lower (P=0.0025), but the % of peak VO₂ at which
226 the AT occurred was similar between groups (P=0.6490), indicating normal
227 metabolic function. Along these lines there were no other indications of defects in
228 muscle metabolic pathways indicating no muscle metabolic limitations to VO₂ peak in
229 either group (i.e. normal peak respiratory exchange ratio (RER) and a normal
230 VO₂/work rate relationship^{37,38} (Table 4). Maximum HR was lower in the long COVID
231 group versus controls, but there was no difference between groups when HR was
232 measured as the % of predicted maximum (P=0.1326). The slope of the HR plotted
233 against the %VO₂ peak was lower in the long COVID group (Table 4; P=0.0114)
234 versus controls indicating a blunted HR response to exercise and potentially some
235 degree of chronotropic incompetence. Heart rate at AT was also lower in the long
236 COVID group versus controls (P=0.0453). Finally, the peak oxygen pulse (VO₂/HR)
237 was lower in the long COVID group versus controls, indicating a cardiovascular
238 limitation to exercise. Despite this, the HR recovery at 1 min was similar between

239 groups ($P=0.4653$); indicating that parasympathetic engagement post-exercise in the
240 long COVID group was similar to control.

241 The VCO_2 at peak was lower in the long COVID group (Table 4; $P=0.0477$), whereas
242 minute ventilation, tidal volume and breathing frequency at peak were similar
243 between groups (Table 4, $P>0.05$). Supplementary figure 3 shows the minute
244 ventilation versus the VCO_2 and VO_2 at rest, AT, and peak exercise in both groups.
245 The mean breathing reserve (max minute ventilation/predicted maximal voluntary
246 ventilation (calculated as $FEV1 * 40$) was similar between groups ($P=0.8708$). Thus it
247 is likely that the lower peak VO_2 in the long COVID group is not a result of pulmonary
248 mechanical limitations^{39,40}.

249 The V_E/VCO_2 ratio at peak (ANOVA; $P=0.0051$) and at AT ($P=0.0477$) was higher in
250 the long COVID group versus control (see Supplementary figure 3 for ANOVA details
251 and V_E/VCO_2 ratio plotted against the VO_2 at rest, AT, and peak exercise). The
252 V_E/VCO_2 slope (Table 4, $P=0.0008$) and the V_E/VCO_2 nadir ($P=0.0020$) during
253 exercise were also higher in the long COVID group versus controls indicating lower
254 breathing efficiency (a higher minute ventilation to remove a given volume of CO_2)
255 indicating hyperventilation at any point during exercise (Figure 1 for example slopes
256 (raw data) in a control and long COVID participant). Thirteen percent of the control
257 group had a V_E/VCO_2 slope higher than the normal range (20-30^{41,42}) versus 88% in
258 the long COVID group. Finally, the $P_{ET}CO_2$ was lower at the AT and at peak exercise
259 in the long COVID group versus the control group (time*group effect; $P=0.0119$,
260 mixed model ANOVA), but the magnitude of rise of the $P_{ET}CO_2$ from rest to AT and
261 from rest to peak exercise was the same in both groups ($P=0.0904$, supplementary
262 figure 4, mixed model ANOVA).

263

264

265

266

267

268 Table 4 - Cardiopulmonary exercise testing data in the control and long COVID
 269 groups.

CPET data	Controls (n=14)	Long COVID (n=14)	P-value
HR at peak (beats/min)	170 ± 17	158 ± 18	0.0619
(% predicted)	97 ± 6	92 ± 9	0.1326
VO ₂ at peak (L/min)	1.78±0.57	1.40±0.34	0.0378
(mL/kg/min)	26.7±7.4	18.6±4.7	0.0015
(% predicted)	91±18	76±18	0.0340
HR/%VO ₂ slope	1.00 ± 0.15	0.77 ± 0.26	0.0114
RER at peak	1.28 ± 0.11	1.27 ± 0.09	0.7483
RPE at peak (median, IQR)	17 (16-18)	19 (18-19)	0.0081*
Dyspnoea at peak (median, IQR)	5 (4-8)	8 (5-9)	0.0515*
SpO ₂ (%) at peak	99 ± 1	99 ± 1	0.8966
VCO ₂ at peak (L/min)	2.29 ± 0.83	1.76 ± 0.52	0.0477
P _{ET} CO ₂ at peak	39.6±4.7	33.6±3.8	0.0007
O ₂ pulse peak (mL/beat)	10.6 ± 2.8	8.9 ± 2.0	0.0650
Peak SBP (mmHg)	177 ± 21	171 ± 26	0.5115
Peak DBP (mmHg)	88 ± 12	90 ± 15	0.6286
V _E at peak (L/min)	71.5± 29.2	66.4±22.4	0.6012
Breathing reserve	43 ± 18	42 ± 24	0.8708
f _B at peak (breaths/min)	36 ± 10	37 ± 9	0.8705
V _T at peak (L)	1.98 ± 0.47	1.83 ± 0.40	0.3440
V _E /VCO ₂ ratio at peak	31.4 ± 4.9	38.7 ± 5.4	0.0005
V _E /VO ₂ ratio at peak	39.8 ± 7.6	48.4 ± 8.6	0.0095
V _E /VCO ₂ slope	27.7 ± 4.8	37.8 ± 4.4	0.0003
Nadir V _E /VCO ₂	25.0 ± 2.4	30.1±5.0	0.0020
VO ₂ at AT (mL/kg/min)	18.7 ± 5.6	12.6 ± 4.3	0.0025
(% of VO ₂ peak)	68 ± 10	66 ± 13	0.6490
P _{ET} CO ₂ at AT (mmHg)	44 ± 4	38 ± 6	0.0041
V _E /VCO ₂ at AT	25.5 ± 2.4	30.4 ± 5.4	0.0042
HR at AT (beats/min)	132 ± 13	121 ± 15	0.0453
(% of peak HR)	76 ± 5	77 ± 8	0.6181

Δ from rest (beats/min)	61 ± 18	38 ± 16	0.0009
VO ₂ /WR slope	8.2 ± 1.2	8.2 ± 1.5	0.9283
Heart rate recovery 1 min (beats/min)	19 ± 7	17 ± 5	0.4635

270 HR; heart rate, VO₂; volume of inspired oxygen, RER; respiratory exchange ratio,
271 RPE; rating of perceived exertion, SpO₂; oxygen saturation, VCO₂; volume of expired
272 carbon dioxide, SBP; systolic blood pressure, DBP; diastolic blood pressure, VE;
273 minute ventilation, Bf; breathing frequency, TV; tidal volume, VE/VCO₂; ventilatory
274 efficiency, AT; anaerobic threshold, P_{ET}CO₂; partial pressure of end-tidal carbon
275 dioxide, WR; work rate.




276

277 *Hypoxic ventilatory response*

278 Figure 1A shows examples carotid chemoreflex tests in a control and a long COVID
279 participants and the resultant hypoxic ventilatory responses (calculated from the
280 minute ventilation) in these participants (Figure 1B). The hypoxic ventilatory
281 response (minute ventilation response to reductions in SpO₂%) was elevated in the
282 long COVID (-0.44 ± 0.23 l/min/ SpO₂%, $R^2=0.77 \pm 0.20$) group compared to controls
283 (-0.17 ± 0.13 l/min/SpO₂%, $R^2=0.54 \pm 0.38$, Figure 2A, $P=0.0007$); thus, for a given
284 decrease in SpO₂, the participants with long COVID had a greater increase in minute
285 ventilation. This was driven by a greater increase in tidal volume (Figure 2B) in the
286 participants with long COVID rather than a greater increase in breathing frequency
287 compared to the controls (Figure 2C). Taken together this indicates that the
288 participants with long COVID have an elevated carotid chemoreflex sensitivity to
289 hypoxia.


290 There was no difference in the HR response to hypoxia (Figure 2D) between groups
291 (control; -0.66 ± 0.35 beats/min/ SpO₂% versus long COVID; -0.58 ± 0.60
292 beats/min/SpO₂%, $P=0.5978$). Additionally, there was no difference in the SBP or
293 DBP response to hypoxia between groups (Figure 2E and 2F). The BP response to
294 hypoxia was variable between individuals with some participants showing a
295 depressor response to hypoxia and others showing a pressor (most common, where
296 the slope of the regression is negative in figure 2E and 2F) or biphasic response to
297 hypoxia.

298 The hypoxic ventilatory response was correlated with the V_E/VCO_2 slope during
299 exercise ($r=0.54$, $P=0.0037$); indicating that the high carotid chemoreflex sensitivity
300 in the long COVID participants may partially explain the higher V_E/VCO_2 slope
301 (poorer breathing efficiency) during exercise. Therefore, the carotid chemoreflex may
302 play an important role in driving hyperventilation or poor breathing efficiency during
303 exercise. Targeting the carotid body or the carotid chemoreflex could be helpful in
304 improving ongoing symptoms in participants with long COVID and improving
305 exercise tolerance.



307 Figure 1 - A) Example carotid chemoreflex test in a control (solid line) and long COVID (dotted line) participants. Data shows the
308 raw SpO₂ response to nitrogen exposure (bottom panel) and the resultant tidal volume, breathing frequency, and minute ventilation
309 responses. The minute ventilation (average of the largest 2 consecutive breaths) is plotted against the nadir SpO₂ for each nitrogen
310 exposure²¹ (panel B). The resultant slope of the linear regression is the hypoxic ventilatory response. Panel C shows the minute
311 ventilation (V_E) plotted against the volume of expired carbon dioxide (VCO₂) for each breath during exercise in the same 2
312 participants. The slope of the regression is the V_E/VCO₂ slope and is used as a measure of breathing efficiency.

313



314

315 Figure 2 - The hypoxic ventilatory response based on A) minute ventilation, B) tidal volume
316 (V_T) and C) breathing frequency (f_B). There was a higher hypoxic ventilatory response
317 based on minute ventilation and tidal volume in the participants with long COVID (n=14)
318 versus control (n=14). Panels D, E and F show the heart rate, systolic and diastolic blood
319 pressure hypoxic responses. Data are the slope of the linear regression where SpO₂% was
320 plotted against the heart rate, and BP during each hypoxic exposure. There was no
321 difference in the HR or BP response to hypoxia between groups.

322

323 Discussion

324 The pathophysiological mechanisms driving ongoing symptoms in patients with long COVID,
325 after an initial mild infection, are unclear. Here we show for the first time that carotid
326 chemoreflex sensitivity is amplified in non-hospitalised patients with long COVID (versus a

327 control group) and that this was correlated with hyperventilation and poor breathing
328 efficiency during exercise. Elevated carotid chemoreceptor activity could explain several of
329 the ongoing symptoms experienced by patients living with long COVID.

330

331 *The hyperventilatory state of long COVID*

332 In this population of participants with long COVID, we show that despite similar lung
333 function (resting spirometry and ventilatory reserve during exercise) to the control group,
334 these participants hyperventilate at rest and during exercise. At rest, this is evidenced by a
335 similar minute ventilation compared to control despite a lower resting $P_{ET}CO_2$. Resting
336 levels of arterial CO_2 provides the key stimulus for respiratory drive, mainly via the central
337 chemoreceptors.⁴³ Reductions in $P_{ET}CO_2$ indicate decreases in $PaCO_2$ ^{44,45} which is a
338 stimulus to lower ventilation; however, this has not occurred in the long COVID participants
339 since their level of ventilation was the same as the controls suggesting a resetting of
340 chemoreceptor set-point for breathing. If resting $P_{ET}CO_2$ levels were restored to normal
341 control levels, it is possible that minute ventilation would be greater in the long COVID
342 group. Additionally, the V_E/VCO_2 ratio at rest is higher in the long COVID participants,
343 showing that they are breathing more to remove the same volume of CO_2 as controls.
344 Altered V_E/VCO_2 ratio (and $P_{ET}CO_2$) could result from changes to gas exchange between
345 the alveoli and pulmonary circulation. However, we found that during exercise the
346 magnitude of the rise in $P_{ET}CO_2$ was the same in the long COVID participants versus the
347 controls. During exercise (with a normal gas exchange) $P_{ET}CO_2$ rises and peaks around
348 anaerobic threshold. When gas exchange is impaired by abnormal ventilation or perfusion
349 of the lung, the $P_{ET}CO_2$ will show smaller rises, no rise, or even decrease as seen in COPD,
350 heart failure and pulmonary hypertension⁴⁶. As such, the similar rise in $P_{ET}CO_2$ with
351 exercise in long COVID patients and control participants suggests no differences in gas
352 exchange between these groups. However, we acknowledge that this needs to be
353 confirmed with gas diffusion studies.

354 We also found evidence of elevated resting V_T/Ti , an index of inspiratory flow, in the long
355 COVID group versus the control group. The V_T/Ti is used as surrogate of primary neural
356 drive for inspiration³⁶ and thus could indicate a higher 'inspiratory drive' at rest in the long
357 COVID participants which may contribute to their feelings of dyspnoea. High inspiratory flow
358 can also indicate changes in airway mechanics⁴⁷, however, this is unlikely in the long

359 COVID group, since resting lung function (spirometry) was similar between groups. During
360 exercise, hyperventilation or poor breathing efficiency was also evidenced by elevated
361 V_E/V_{CO_2} slopes and an elevated V_E/V_{CO_2} ratio at anaerobic threshold and peak exercise.
362 Since the carotid chemoreflex plays an important part in the control of breathing both at rest
363 and exercise (including inspiratory drive⁴⁸); it is possible that it is contributing to
364 hyperventilation in long COVID.

365

366 *Carotid chemoreflex*

367 The mammalian carotid chemoreflex is a protective reflex that contributes to ventilatory and
368 cardiovascular control⁴⁹. In addition to signalling the need for increased ventilation during
369 hypoxia (and other stimuli¹⁹), the carotid body chemoreceptors contribute to resting
370 ventilatory drive, as demonstrated by their tonic activity in humans and animal models^{48,50}.
371 It is well established that certain disease states exhibit exaggerated carotid chemoreflex
372 sensitivity²⁰ and tonicity¹⁸. Given that elevated carotid chemoreflex sensitivity measured by
373 the hypoxic ventilatory response predicts symptom burden, exercise intolerance, dyspnoea,
374 and hyperventilation in heart failure^{21,51}, we aimed to assess carotid chemoreflex sensitivity
375 in long COVID. The hypoxic ventilatory response was 145% higher in the long COVID
376 group versus age-, BMI- and sex-matched controls indicating amplified carotid
377 chemoreceptor sensitivity in the long COVID group. The higher hypoxic ventilatory
378 response was observed despite a lower resting $P_{ET}CO_2$ in the long COVID group even
379 though hypocapnia normally depresses carotid chemoreflex sensitivity to hypoxia⁵². The
380 hypoxic ventilatory response was in fact similar to that measured in a group of patients with
381 heart failure reduced ejection fraction in our lab (-0.44 ± 0.23 L/min/SpO₂% versus $-0.48 \pm$
382 0.30 L/min/SpO₂%; mean \pm SD) using the same equipment before March 2020 (see
383 supplementary Figure 5). The elevated hypoxic ventilatory response in the long COVID
384 participants was driven by amplified responses in tidal volume rather than breathing
385 frequency, which supports previous reports in humans where the increase in minute
386 ventilation during mild hypoxia is driven mainly by increases in tidal volume⁵³.

387 The hypoxic ventilatory response was correlated with the V_E/V_{CO_2} slope, so that a person
388 with high chemoreflex sensitivity had a higher V_E/V_{CO_2} slope (or vice versa). This suggests
389 that elevated carotid chemoreflex sensitivity may partially explain reduced breathing
390 efficiency and hyperventilation during exercise in participants with long COVID^{14,15,17}. In fact,

391 breathing efficiency was poor in some of the participants in this study; 64% of the long
392 COVID group had a V_E/V_{CO_2} slope >34 (versus only 7% (one person) in the control group),
393 which is a powerful prognostic indicator of future outcomes for people with heart failure⁵⁴. It
394 is possible that in long COVID the carotid chemoreflex has a similar function as that
395 described heart failure, partially explaining the dysregulated breathing and feelings of
396 breathlessness in patients with ongoing symptoms after their initial mild infection. Elevated
397 V_E/V_{CO_2} slopes are also caused by increased dead space ventilation due to 1) inadequate
398 aeration of the alveoli and 2) poor perfusion of the aerated lung spaces, affecting gas
399 exchange. However, in this study there was no evidence of mechanical lung or small airway
400 issues (due to a similar prevalence of normal breathing reserve in the two groups and
401 similar resting spirometry between the groups). No obvious evidence of gas exchange
402 issues were observed either, because the $P_{ET}CO_2$ during exercise (to AT) increased by a
403 similar magnitude in the participants with long COVID versus the controls.

404 Finally, the resting $P_{ET}CO_2$ was <30 mmHg in 4 participants with long COVID. Low $P_{ET}CO_2$
405 causes similar symptoms as those often experienced by patients with long COVID including
406 feelings of brain fog (due to poor cerebral perfusion) and paraesthesia⁵⁵. The level of
407 $P_{ET}CO_2$ however did not reach apnoeic threshold levels⁵⁶ in any patients because there
408 were no apnoeas at rest and no evidence of periodic breathing patterns⁵⁷. Low resting
409 $P_{ET}CO_2$ and hyperventilation is a hallmark of hyperventilatory syndrome which has been
410 cited as a cause of ongoing in symptoms in some cohorts of patients with long COVID⁵⁸. It
411 is possible that problems with breathing at rest and during exercise, leading to lower
412 $P_{ET}CO_2$ levels and manifesting as hyperventilation syndrome could be partially driven by
413 the carotid chemoreflex in patients with long COVID.

414 *Mechanisms*

415 Possible mechanisms of increased carotid chemoreceptor sensitivity after SARS-CoV-2
416 infection include local changes within the parenchyma of the carotid body and/or
417 dysfunction occurring in medullary regions that process afferent sensory information and
418 control efferent ventilatory responses.

419 In the acute phase of the infection, local viral and immune cell invasion of the carotid body²⁵
420 could disrupt normal functioning, potentially via immune cells destroying infected glomus
421 cells explaining silent hypoxia in some patients²³. In the long-term these cells are likely
422 replaced but there is the possibility of long-term local inflammation and disruption of ACE1

423 and ACE2 balance leading to elevated carotid chemoreceptor drive. Additionally, since the
424 carotid bodies are highly sensitive to disturbances in perfusion, any blood flow disruption
425 caused by microthrombi and endothelial dysfunction²⁵ could elevate carotid body activity⁵⁹.
426 It is also possible that dysfunction of the petrosal ganglion, which carries afferent sensory
427 input into the brainstem, causes hyper-reactivity in the carotid chemoreflex. Of note, the
428 petrosal ganglion participates in mediating taste signals in the brain. However, only 7% of
429 our long COVID participants reported ongoing impaired sense of taste and smell¹¹.
430 Additionally, inflammation or neuronal damage in the medullary regions mediating afferent
431 signals from the carotid body could contribute to increased chemoreceptor drive. Along
432 these lines there is evidence from animal models that the original SARS-CoV infiltrates
433 medullary brain regions⁶⁰, but there is no strong evidence of this occurring with existing
434 variants of SARS-CoV-2.

435 Finally, some evidence suggests the SARS-CoV-2 may affect mitochondrial function⁶¹. The
436 glomus cells in the carotid body have unique mitochondria, which are important for O₂
437 sensing⁶². Any mitochondrial dysfunction in glomus cells could lead to augmented
438 chemoreflex activity⁶². Since mitochondrial dysfunction could occur in any organ, the
439 exercise intolerance and hyperventilation observed in long COVID could also be driven, for
440 example, by the metaboreceptors in skeletal muscle due to poor mitochondrial function and
441 this needs to be examined.

442 *Limitations*

443 Firstly, the control group are a combination of prospectively recruited participants who
444 recovered from a SARS-CoV-2 infection in <4 weeks, and participants who were
445 retrospectively identified from our previous studies (all measures were taken using the
446 same equipment, procedures, and site). Thus 6 of the controls did not have a previous
447 SARS-CoV-2 infection. We cannot rule out that SARS-CoV-2 infection has long lasting
448 effects of the cardiopulmonary system even if individuals recover with no ongoing
449 symptoms. Secondly, we measured the carotid chemoreflex sensitivity using poikilocapnic
450 hypoxia, thus P_{ET}CO₂ decreased after each hypoxic exposure (due to ventilatory
451 adjustments). However, it is unlikely that this affected the ventilatory response to hypoxia
452 because 1) the P_{ET}CO₂ decreased only after the breaths that were used as measurements
453 for ventilation and thus could not affect the data and 2) we waited for the P_{ET}CO₂ to return
454 to baseline after each hypoxic exposure. Thirdly, this was a single site study with a small

455 sample size and thus needs to be evaluated in a larger population of patients with long
456 COVID. Finally, although we see evidence of elevated carotid chemoreceptor sensitivity in
457 patients with long COVID, we need to evaluate whether dampening down the hyperreflexia
458 helps to improve symptoms.

459 *Implications*

460 Here we show for the first time that patients with long COVID have elevated carotid
461 chemoreceptor sensitivity and that this is correlated with poor breathing efficiency or
462 hyperventilation during exercise. Interventions that temper carotid body excitability could be
463 explored as a treatment option for long COVID. Previously our group had shown that P2X3
464 receptors in the carotid body can be targeted to reduce carotid chemoreflex hyperreflexia in
465 an animal model of hypertension¹⁸ and heart failure⁶³, and could be a viable target in
466 humans with long COVID. Gefapixant, an oral P2X3 receptor antagonist, has recently
467 demonstrated efficacy and an acceptable safety profile in chronic cough in phase 3 clinical
468 trials⁶⁴. P2X3 receptors could therefore be a viable target in humans with long COVID.

469

470 **Methods**

471 *Design*

472 This was a single-site case-control study.

473 *Participants*

474 Ethical approval for the study was granted by South Central Hampshire NHS Research
475 Ethics Committee (21/SC/0260) and the Health Research Authority. Participants gave their
476 written informed consent. All participants were asked to abstain from intense exercise and
477 alcohol consumption 24 hours before the study. All experimental protocols conformed to the
478 Declaration of Helsinki. Inclusion criteria for all participants were; aged 18-80 years and a
479 positive SARS-CoV-2 antibody test before vaccination, or a positive COVID-19 PCR
480 antigen swab test. Long COVID participants had received a diagnosis of long COVID,
481 where symptoms developed during or after an infection consistent with COVID-19 and
482 continued for more than 12 weeks (and could not be explained by an alternative diagnosis)
483 as per NHS (UK) National Institute for Health and Care Excellence guidelines⁶⁵.

484 Participants without long COVID had symptoms lasting less than 4 weeks after their initial
485 infection. See the online-only Supplement for exclusion criteria.

486 *Experimental protocol*

487 Participants attended the NIHR Bristol Clinical Research facility for 2 studies, completed at
488 the same time of day, and the laboratory conditions were at a set temperature (22°C). In
489 visit one, informed consent, in-depth medical history, clinic blood pressure assessment, sit-
490 to-stand test for orthostatic intolerance, lung function tests (spirometry), 12-lead ECG,
491 pregnancy tests and a symptom limited incremental cardiopulmonary exercise test were
492 completed. The second visit involved resting ventilation and cardiovascular measurements
493 followed by carotid chemoreflex assessment via the hypoxic ventilatory response.

494 *Procedures*

495 *Clinic blood pressure:* Participants rested in a chair for 10 minutes prior to clinic BP being
496 assessed (Omron, 705IT, Omron Healthcare, Kyoto, Japan). Clinic BP was assessed in-line
497 with European Hypertension Society Guidelines⁶⁶

498 *Orthostatic intolerance* was assessed using a sit-to-stand test using the HYVET protocol³⁴
499 where BP was measured when sitting, immediately upon standing, and after 1, 2 and 3
500 minutes of standing.

501 *Resting spirometry:* Resting spirometry was used to assess lung function, to ensure no
502 mechanical lung function abnormalities were present. Spirometry (Ergostick, CPET system,
503 LoveMedical, UK) was completed in line with the joint American Thoracic and European
504 Respiratory Society guidelines⁶⁷. The Global Lung Function Initiative (GLI) network
505 reference values were used to calculate the percentage of predicted values and z-scores⁶⁸.

506 *12-lead ECG:* Resting 12-lead ECG was performed and checked by a Cardiologist at the
507 Bristol Heart Institute for any ECG abnormalities, and to clear participants to exercise.

508

509 *Cardiopulmonary exercise testing*

510 After acclimatisation to the facemask and sitting on the cycle ergometer, participants
511 completed a 5-minute steady state resting period followed by 3 minutes of unloaded cycling.
512 Participants then completed a continuous ramp incremental exercise test to volitional
513 exhaustion where work rate increased by 15-30 W depending on their physical ability.

514 Exercise tests were completed on an electronically braked cycle ergometer (Ergoselect 5;
515 Ergoline, Germany). Cardiorespiratory data were recorded using a metabolic measurement
516 system (Ergostik; LoveMedical, UK) with integrated 12-lead ECG and finger pulse oximetry
517 for heart rate and SpO₂% monitoring. Brachial arterial blood pressure was measured via an
518 integrated automated auscultatory blood pressure cuff (LoveMedical, UK. Ratings of
519 perceived exertion (6-20 Borg scale) and dyspnoea scores (modified Borg scale) were
520 obtained at rest, and every minute during exercise, and at the end of exercise. Peak
521 cardiopulmonary data were averaged over the last 30 seconds of exercise. The anaerobic
522 threshold was measured via the V-slope method and Dual Criterion methods as
523 recommended by the American Thoracic Society guidelines⁶⁹. The minute ventilation and
524 VCO₂ values from initiation to peak exercise were used to measure V_E/VCO₂ slope via least
525 squares linear regression⁷⁰.

526

527 *Carotid chemoreflex assessment*

528 Resting carotid chemoreceptor sensitivity tests were completed with participants in a semi-
529 supine position with continuous monitoring of beat-to-beat blood pressure (Finapres), SpO₂
530 (ear-lobe pulse oximeter; Radical-7; Masimo Corp, USA), heart rate (lead II of 3-lead ECG,
531 AD Instruments, Australia). Simultaneously, ventilation was measured via a facemask
532 attached to a one-way non-rebreathing circuit (Hans Rudolph, Inc., USA). The inhalation
533 part of the circuit delivered room air or 100% nitrogen gas (transiently) for carotid
534 chemosensitivity testing. The exhalation arm of the circuit was connected to a gas analyser
535 (Ad Instruments) and flow head (MLT3000L; AD Instruments) fitted with a differential
536 pressure transducer (FE141 Spirometer; AD Instruments) for the measurement of inspired
537 and expired fractions of O₂ and CO₂, tidal volume, breathing frequency and minute
538 ventilation. All data were continuously monitored and recorded with a data acquisition
539 system (Powerlab 16/30; AD Instruments) and stored for subsequent analyses using
540 associated software (LabChart 8.0 Pro; AD Instruments).

541

542 The transient hypoxic ventilatory response test was used to measure the sensitivity of the
543 carotid chemoreflex^{21,71}. After a period of quiet rest breathing room air (10 mins baseline),
544 the researcher added extra-nitrogen to the room air being delivered to the face-mask.
545 Nitrogen gas administration was controlled silently using a high-pressure electric valve. The

546 nitrogen blended into the room air was delivered for 2-8 breaths, followed by a 3-minute
547 recovery period or until ventilation and haemodynamic variables returned to baseline levels.
548 This was repeated 6-8 times to obtain a range of oxygen saturations (SpO₂: ~70–100%).
549 The average of the two largest consecutive breaths in the 1 minute preceding the nitrogen
550 exposure was used to calculate the ventilatory response to reductions in SpO₂%²⁰. The
551 hypoxic ventilatory response was evaluated as the slope of the linear regression relating
552 the minute ventilation to the nadir of SpO₂ for each nitrogen exposure^{20,71} (Figure 1B). The
553 response of tidal volume and breathing frequency to reductions in SpO₂ were also
554 evaluated in the same way as that for minute ventilation.

555 The peak heart rate and blood pressure was determined following each hypoxic challenge
556 using a 3-beat rolling average and plotted against the nadir oxygen saturation. The hypoxic
557 heart rate (beats/min/%) and blood pressure (mmHg/%) were calculated as the slope of the
558 simple linear regression obtained from baseline and the hypoxic challenges.

559

560 *Statistical analysis*

561 Statistical analyses were completed in GraphPad Prism (V9.5.1). Participant demographics,
562 resting spirometry, cardiopulmonary exercise and hypoxic ventilatory response data were
563 analysed using an independent samples t-test or Mann Whitney U test if data were not
564 normally distributed or were non-parametric. Where data are compared across multiple time
565 points between the groups, a mixed model ANOVA was used with a Bonferroni correction
566 for pairwise comparisons. Data are reported as mean ± standard deviation or median
567 (interquartile range) unless otherwise stated. A significance level of $\alpha < 0.05$ was used for all
568 analyses.

569

570 **Disclosures**

571 None.

572

573 **Funding**

574 This work was supported by the Elizabeth Blackwell Institute, University of Bristol and the
575 Bristol and Weston Hospitals Charity pump priming scheme.

576

577 **Acknowledgements**

578 Thank you to the participants who took part (despite their often-debilitating symptoms), the
579 study would not have been possible without them. Thank you also to the cardiology
580 research nurses who helped support this study.

581

582 **References**

- 583 1. Venkatesan, P. NICE guideline on long COVID. *Lancet Respir Med* **9**, 129 (2021).
- 584 2. Thompson, E.J., *et al.* Long COVID burden and risk factors in 10 UK longitudinal studies and
585 electronic health records.
- 586 3. Ahmad, I., *et al.* High prevalence of persistent symptoms and reduced health-related quality
587 of life 6 months after COVID-19. *Front Public Health* **11**, 1104267 (2023).
- 588 4. Augustin, M., *et al.* Post-COVID syndrome in non-hospitalised patients with COVID-19: a
589 longitudinal prospective cohort study. *Lancet Reg Health Eur* **6**, 100122 (2021).
- 590 5. O'Mahoney, L.L., *et al.* The prevalence and long-term health effects of Long Covid among
591 hospitalised and non-hospitalised populations: a systematic review and meta-analysis.
592 *eClinicalMedicine* **55**, 101762 (2023).
- 593 6. Huang, C., *et al.* 6-month consequences of COVID-19 in patients discharged from hospital: a
594 cohort study. *Lancet* **397**, 220-232 (2021).
- 595 7. Antonelli, M., *et al.* Risk factors and disease profile of post-vaccination SARS-CoV-2
596 infection in UK users of the COVID Symptom Study app: a prospective, community-based,
597 nested, case-control study. *Lancet Infect Dis* **22**, 43-55 (2022).
- 598 8. (ONS), O.f.N.S. Prevalence of ongoing symptoms following coronavirus (COVID-19)
599 infection in the UK: 2 February 2023. (ONS website, statistical bulletin, 2023).
- 600 9. Whitaker, M., *et al.* Persistent COVID-19 symptoms in a community study of 606,434 people
601 in England.
- 602 10. Ballering, A.V., van Zon, S.K.R., Olde Hartman, T.C. & Rosmalen, J.G.M. Persistence of
603 somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. *Lancet*
604 **400**, 452-461 (2022).
- 605 11. Alkodaymi, M.S., *et al.* Prevalence of post-acute COVID-19 syndrome symptoms at different
606 follow-up periods: a systematic review and meta-analysis. *Clin Microbiol Infect* **28**, 657-666
607 (2022).
- 608 12. Davis, H.E., McCorkell, L., Vogel, J.M. & Topol, E.J. Long COVID: major findings,
609 mechanisms and recommendations. *Nat Rev Microbiol* **21**, 133-146 (2023).

- 610 13. Davis, H.E., McCorkell, L., Vogel, J.M. & Topol, E.J. Long COVID: major findings,
611 mechanisms and recommendations. *Nature Reviews Microbiology* **21**, 133-146 (2023).
- 612 14. Durstenfeld, M.S., *et al.* Use of Cardiopulmonary Exercise Testing to Evaluate Long COVID-
613 19 Symptoms in Adults: A Systematic Review and Meta-analysis. *JAMA Netw Open* **5**,
614 e2236057 (2022).
- 615 15. Singh, I., *et al.* Persistent Exertional Intolerance After COVID-19: Insights From Invasive
616 Cardiopulmonary Exercise Testing. *Chest* **161**, 54-63 (2022).
- 617 16. van Voorthuizen, E.L., van Helvoort, H.A.C., Peters, J.B., van den Heuvel, M.M. & van den
618 Borst, B. Persistent Exertional Dyspnea and Perceived Exercise Intolerance After Mild
619 COVID-19: A Critical Role for Breathing Dysregulation? *Phys Ther* **102**(2022).
- 620 17. Frésard, I., *et al.* Dysfunctional breathing diagnosed by cardiopulmonary exercise testing in
621 'long COVID' patients with persistent dyspnoea. *BMJ Open Respir Res* **9**(2022).
- 622 18. Pijacka, W., *et al.* Purinergic receptors in the carotid body as a new drug target for
623 controlling hypertension. *Nat Med* **22**, 1151-1159 (2016).
- 624 19. Iturriaga, R., Alcayaga, J., Chapleau, M.W. & Somers, V.K. Carotid body chemoreceptors:
625 physiology, pathology, and implications for health and disease. *Physiol Rev* **101**, 1177-1235
626 (2021).
- 627 20. Ponikowski, P., *et al.* Peripheral chemoreceptor hypersensitivity: an ominous sign in patients
628 with chronic heart failure. *Circulation* **104**, 544-549 (2001).
- 629 21. Chua, T.P., *et al.* Clinical characteristics of chronic heart failure patients with an augmented
630 peripheral chemoreflex. *Eur Heart J* **18**, 480-486 (1997).
- 631 22. Lan, J., *et al.* Structure of the SARS-CoV-2 spike receptor-binding domain bound to the
632 ACE2 receptor. *Nature* **581**, 215-220 (2020).
- 633 23. Villadiego, J., *et al.* Is Carotid Body Infection Responsible for Silent Hypoxemia in COVID-19
634 Patients? *Function (Oxf)* **2**, zqaa032 (2021).
- 635 24. Villadiego, J., *et al.* Is Carotid Body Infection Responsible for Silent Hypoxemia in COVID-19
636 Patients? *Function* **2**(2020).
- 637 25. Porzionato, A., *et al.* Case Report: The Carotid Body in COVID-19: Histopathological and
638 Virological Analyses of an Autopsy Case Series. *Front Immunol* **12**, 736529 (2021).
- 639 26. Lambermont, B., Davenne, E., Maclot, F. & Delvenne, P. SARS-CoV-2 in carotid body.
640 *Intensive Care Med* **47**, 342-343 (2021).
- 641 27. Schultz, H.D. Angiotensin and carotid body chemoreception in heart failure. *Curr Opin*
642 *Pharmacol* **11**, 144-149 (2011).
- 643 28. Allen, A.M. Angiotensin AT1 receptor-mediated excitation of rat carotid body chemoreceptor
644 afferent activity. *J Physiol* **510 (Pt 3)**, 773-781 (1998).
- 645 29. Li, Y.L., *et al.* Angiotensin II enhances carotid body chemoreflex control of sympathetic
646 outflow in chronic heart failure rabbits. *Cardiovasc Res* **71**, 129-138 (2006).

- 647 30. Rysz, S., *et al.* COVID-19 pathophysiology may be driven by an imbalance in the renin-
648 angiotensin-aldosterone system. *Nat Commun* **12**, 2417 (2021).
- 649 31. Shah, W., Hillman, T., Playford, E.D. & Hishmeh, L. Managing the long term effects of covid-
650 19: summary of NICE, SIGN, and RCGP rapid guideline. *BMJ* **372**, n136 (2021).
- 651 32. Cervia, C., *et al.* Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome.
652 *Nature Communications* **13**, 446 (2022).
- 653 33. Sylvester, K.P., *et al.* ARTP statement on pulmonary function testing 2020. *BMJ Open*
654 *Respir Res* **7**(2020).
- 655 34. Peters, R., *et al.* Orthostatic hypotension and symptomatic subclinical orthostatic
656 hypotension increase risk of cognitive impairment: an integrated evidence review and
657 analysis of a large older adult hypertensive cohort. *Eur Heart J* **39**, 3135-3143 (2018).
- 658 35. Peters, R., *et al.* Orthostatic hypotension and symptomatic subclinical orthostatic
659 hypotension increase risk of cognitive impairment: an integrated evidence review and
660 analysis of a large older adult hypertensive cohort. *European Heart Journal* **39**, 3135-3143
661 (2018).
- 662 36. Morgan, B.J., Adrian, R., Bates, M.L., Dopp, J.M. & Dempsey, J.A. Quantifying hypoxia-
663 induced chemoreceptor sensitivity in the awake rodent. *Journal of applied physiology* **117**,
664 816-824 (2014).
- 665 37. Riley, M.S., Nicholls, D.P. & Cooper, C.B. Cardiopulmonary Exercise Testing and Metabolic
666 Myopathies. *Ann Am Thorac Soc* **14**, S129-S139 (2017).
- 667 38. Riley, M.S., Nicholls, D.P. & Cooper, C.B. Cardiopulmonary Exercise Testing and Metabolic
668 Myopathies. *Annals of the American Thoracic Society* **14**, S129-S139 (2017).
- 669 39. Glaab, T. & Taube, C. Practical guide to cardiopulmonary exercise testing in adults. *Respir*
670 *Res* **23**, 9 (2022).
- 671 40. Glaab, T. & Taube, C. Practical guide to cardiopulmonary exercise testing in adults.
672 *Respiratory Research* **23**, 9 (2022).
- 673 41. Balady, G.J., *et al.* Clinician's Guide to cardiopulmonary exercise testing in adults: a
674 scientific statement from the American Heart Association. *Circulation* **122**, 191-225 (2010).
- 675 42. Balady, G.J., *et al.* Clinician's Guide to cardiopulmonary exercise testing in adults: a
676 scientific statement from the American Heart Association. *Circulation* **122**, 191-225 (2010).
- 677 43. Guyenet, P.G. & Bayliss, D.A. Central respiratory chemoreception. *Handb Clin Neurol* **188**,
678 37-72 (2022).
- 679 44. Jones, N.L., Robertson, D.G. & Kane, J.W. Difference between end-tidal and arterial PCO₂
680 in exercise. *J Appl Physiol Respir Environ Exerc Physiol* **47**, 954-960 (1979).
- 681 45. Jones, N.L., Robertson, D.G. & Kane, J.W. Difference between end-tidal and arterial PCO₂
682 in exercise. *Journal of applied physiology* **47**, 954-960 (1979).

- 683 46. Hansen, J.E., Ulubay, G., Chow, B.F., Sun, X.G. & Wasserman, K. Mixed-expired and end-
684 tidal CO₂ distinguish between ventilation and perfusion defects during exercise testing in
685 patients with lung and heart diseases. *Chest* **132**, 977-983 (2007).
- 686 47. Younes, M. *Measurement and testing of respiratory drive*, (Dekker, 1981).
- 687 48. Blain, G.M., Smith, C.A., Henderson, K.S. & Dempsey, J.A. Contribution of the carotid body
688 chemoreceptors to eupneic ventilation in the intact, unanesthetized dog. *Journal of applied*
689 *physiology* **106**, 1564-1573 (2009).
- 690 49. Paton, J.F., *et al.* The carotid body as a therapeutic target for the treatment of
691 sympathetically mediated diseases. *Hypertension* **61**, 5-13 (2013).
- 692 50. Dejours, P. Chemoreflexes in Breathing. *Physiological Reviews* **42**, 335-358 (1962).
- 693 51. Giannoni, A., *et al.* Combined Increased Chemosensitivity to Hypoxia and Hypercapnia as a
694 Prognosticator in Heart Failure. *Journal of the American College of Cardiology* **53**, 1975-
695 1980 (2009).
- 696 52. Smith, C.A., Harms, C.A., Henderson, K.S. & Dempsey, J.A. Ventilatory effects of specific
697 carotid body hypocapnia and hypoxia in awake dogs. *Journal of applied physiology* **82**, 791-
698 798 (1997).
- 699 53. Tipton, M.J., Harper, A., Paton, J.F.R. & Costello, J.T. The human ventilatory response to
700 stress: rate or depth? *J Physiol* **595**, 5729-5752 (2017).
- 701 54. Gitt, A.K., *et al.* Exercise anaerobic threshold and ventilatory efficiency identify heart failure
702 patients for high risk of early death. *Circulation* **106**, 3079-3084 (2002).
- 703 55. Gluck, S.L. Acid-base. *Lancet* **352**, 474-479 (1998).
- 704 56. Skatrud, J.B. & Dempsey, J.A. Interaction of sleep state and chemical stimuli in sustaining
705 rhythmic ventilation. *J Appl Physiol Respir Environ Exerc Physiol* **55**, 813-822 (1983).
- 706 57. Xie, A., Skatrud, J.B., Puleo, D.S., Rahko, P.S. & Dempsey, J.A. Apnea-hypopnea threshold
707 for CO₂ in patients with congestive heart failure. *Am J Respir Crit Care Med* **165**, 1245-1250
708 (2002).
- 709 58. Taverne, J., *et al.* High incidence of hyperventilation syndrome after COVID-19. *J Thorac Dis*
710 **13**, 3918-3922 (2021).
- 711 59. Ding, Y., Li, Y.L. & Schultz, H.D. Role of blood flow in carotid body chemoreflex function in
712 heart failure. *J Physiol* **589**, 245-258 (2011).
- 713 60. Netland, J., Meyerholz, D.K., Moore, S., Cassell, M. & Perlman, S. Severe acute respiratory
714 syndrome coronavirus infection causes neuronal death in the absence of encephalitis in
715 mice transgenic for human ACE2. *J Virol* **82**, 7264-7275 (2008).
- 716 61. Guntur, V.P., *et al.* Signatures of Mitochondrial Dysfunction and Impaired Fatty Acid
717 Metabolism in Plasma of Patients with Post-Acute Sequelae of COVID-19 (PASC).
718 *Metabolites* **12**(2022).

- 719 62. Holmes, A.P., Turner, P.J., Buckler, K.J. & Kumar, P. Moderate inhibition of mitochondrial
720 function augments carotid body hypoxic sensitivity. *Pflugers Arch* **468**, 143-155 (2016).
- 721 63. Lataro, R.M., *et al.* P2X3 receptor antagonism attenuates the progression of heart failure.
722 *Nat Commun* **14**, 1725 (2023).
- 723 64. McGarvey, L.P., *et al.* Efficacy and safety of gefapixant, a P2X(3) receptor antagonist, in
724 refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results
725 from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. *Lancet*
726 **399**, 909-923 (2022).
- 727 65. Excellence, N.I.f.H.a.C. COVID-19 rapid guideline: managing the long-term effects of
728 COVID-19. **NG188**(2020).
- 729 66. Williams, B., *et al.* 2018 Practice guidelines for the management of arterial hypertension of
730 the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC).
731 *Blood Press* **27**, 314-340 (2018).
- 732 67. Graham, B.L., *et al.* Standardization of Spirometry 2019 Update. An Official American
733 Thoracic Society and European Respiratory Society Technical Statement. *Am J Respir Crit*
734 *Care Med* **200**, e70-e88 (2019).
- 735 68. Quanjer, P.H., *et al.* Multi-ethnic reference values for spirometry for the 3-95-yr age range:
736 the global lung function 2012 equations. *Eur Respir J* **40**, 1324-1343 (2012).
- 737 69. ATS/ACCP Statement on cardiopulmonary exercise testing. *Am J Respir Crit Care Med* **167**,
738 211-277. (2003).
- 739 70. Arena, R., *et al.* Development of a ventilatory classification system in patients with heart
740 failure. *Circulation* **115**, 2410-2417 (2007).
- 741 71. Chua, T.P. & Coats, A.J. The reproducibility and comparability of tests of the peripheral
742 chemoreflex: comparing the transient hypoxic ventilatory drive test and the single-breath
743 carbon dioxide response test in healthy subjects. *Eur J Clin Invest* **25**, 887-892 (1995).
- 744